Team:EPF Lausanne/Project

From 2010.igem.org

(Difference between revisions)
(Overview)
(Results)
 
(71 intermediate revisions not shown)
Line 19: Line 19:
= Overview =
= Overview =
-
<p align="justify">
+
This page provides an overview of our project and the [[Team:EPF_Lausanne/Project#Results|results]] we achieved.
-
[[Image:Mousquito and asaia 3.png|left|300px|caption]]
+
==Project idea==
-
The aim of our project is to help stopping the propagation of [https://2010.igem.org/wiki/index.php?title=Team:EPF_Lausanne/Project_malaria Malaria]. To do so, we chose to act on the mosquito. Indeed, if we prevent the mosquito from being infected by malaria, it won't be able to transmit the parasite to healthy humans.
+
[[Image:Mousquito and asaia 3.png|left|250px|caption]]
-
</p>
+
The aim of our project is to defeat [https://2010.igem.org/wiki/index.php?title=Team:EPF_Lausanne/Project_malaria Malaria]. To do so, we genetically modified a bacterium that is naturally present in ''Anopheles'' mosquitoes. Our engineered bacterium is designed to prevent malaria from infecting the mosquito. This in turn will prevent the transmission of the parasite to humans.
-
[[Image:mousquito.png|center|200px|caption]]
 
-
Our idea is to engineer [https://2010.igem.org/Team:EPF_Lausanne/Project_asaia Asaia], a bacterium that is naturally present in the mosquito's intestinal tract.  
+
Our idea is to engineer [https://2010.igem.org/Team:EPF_Lausanne/Project_asaia ''Asaia''], a bacterium that is naturally present in the mosquito's intestinal tract.  
[[Image:Asaia_project_overview.png|left|300px]]
[[Image:Asaia_project_overview.png|left|300px]]
Line 33: Line 32:
-
This bacteria would express an [https://2010.igem.org/Team:EPF_Lausanne/Project_immuno immunotoxin] and specific [https://2010.igem.org/Team:EPF_Lausanne/Project_immuno proteins] to kill the (i)Plasmodium falciparum(/i) or prevent its entry into the epithelium.
+
This bacterium would express an [https://2010.igem.org/Team:EPF_Lausanne/Project_immuno immunotoxin] or specific [https://2010.igem.org/Team:EPF_Lausanne/Project_immuno proteins] that either kill ''P. falciparum'' or prevent its entry into the epithelium of ''Anopheles''.
-
 
+
-
 
+
-
    [[Image:all_team.png|200px|caption]]                [[Image:hunting.png|200px|caption]]
+
-
 
+
-
The immunotoxin and the proteins then fight the (i)Plasmodium falciparum (/i) and thus prevent the mosquito infection.
+
-
 
+
-
 
+
 +
[[Image:all_team.png|200px|caption]]                [[Image:hunting.png|200px|caption]]
 +
Our host bacterium ''Asaia'' is an organism that is not only easy to grow and to genetically manipulate but is also naturally present in the ecosystem. We aim to establish ''Asaia'' as a new chassis to give future iGEM teams the opportunity to quickly and efficiently engineer new and more potent ''Asaia'' strains. This would provide synthetic biology with a useful tool in the fight against malaria and other mosquito borne diseases.
[[Image:Zorro.png|right|300px|caption]]
[[Image:Zorro.png|right|300px|caption]]
-
So... ASAIA is the pink power against malaria.....
+
So... ''ASAIA'' is the pink power against malaria.....
Line 56: Line 50:
 +
For an overview of our project, you can watch our movie
 +
[https://2010.igem.org/Team:EPF_Lausanne/Humanpractices_Movie iGEM EPFL movie]
 +
[[Image:Movie chair.png|center|100px|caption]]
 +
==Results==
 +
[[Image:EPFL check list results.png|right|380px|caption]]
-
For a playful overview of our project, you can watch our great movie
+
We established [https://2010.igem.org/Team:EPF_Lausanne/Project_asaia ''Asaia'' as a new chassis] by providing detailed [[Team:EPF_Lausanne/Project_asaia#Do you want to work with Asaia?|tech-sheets]] on how to manipulate it.
-
[https://2010.igem.org/Team:EPF_Lausanne/Humanpractices_Movie iGEM EPFL movie]
+
We constructed several [https://2010.igem.org/Team:EPF_Lausanne/Project_parts biobricks] with which [https://2010.igem.org/Team:EPF_Lausanne/Project_immuno proteins] can be produced that may block [https://2010.igem.org/wiki/index.php?title=Team:EPF_Lausanne/Project_malaria malaria] infection. We also made Asaia-specific biobricks, such as the [[Team:EPF_Lausanne/Project_parts#Promoter_characterization|CFP construct to test expression]].
-
 
+
These tools will allow future iGEM teams to use ''Asaia'' and manipulate it
-
[[Image:Movie chair.png|center|100px|caption]]
+
to fight mosquito-borne diseases.
-
= Further improvements =
+
The [[Team:EPF_Lausanne/Project_immuno#Results|expression of the proteins]] intended to block ''P. falciparum'' was tested in ''E. coli''. The tests showed that the immunotoxin is expressed and it also appears in the supernatant, which is evidence for secretion.
 +
We could not show expression of the P-proteins, probably due to the AT-rich sequence.
-
The next step would be to test Asaia that expresses the immunotoxin in mosquitoes. The efficiency of the immunotoxin could then be measured by counting the number of oocysts outside the mosquito's gut. We are currently collaborating with the Pasteur Institute in Paris to make further test on mosquitoes with our bacteria but unfortunately the results won't be available before this year's jamboree.
+
Furthermore we tested the [[Team:EPF_Lausanne/Project_droso#I) Experiments on Drosophila|persistence of ''Asaia'' in ''D. melanogaster'']] to see if it could be used as an alternative host to facilitate research. The results showed that ''Asaia'' is not persistent in ''D. melanogaster'' and we assume that it is because ''Asaia'' is very specific to mosquitoes.  
-
Some modeling experiments should also be done to try to measure the impact of introducing our modified bacteria in mosquitoes populations. According to the [http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VRT-4V3K67R-B&_user=164550&_coverDate=12%2F09%2F2008&_rdoc=1&_fmt=high&_orig=search&_origin=search&_sort=d&_docanchor=&view=c&_acct=C000013218&_version=1&_urlVersion=0&_userid=164550&md5=52110befa7e6dce2da04feff33af38dc&searchtype=a literature], Asaia is transmitted from parent to offspring and also from one individual to the other but further measurement should be made to see how quick the spreading would be. Using these values, it might be possible to find out the best way to infect the most mosquitoes without risking an uncontrolled expansion of the bacteria population.
+
We also established a [[Team:EPF_Lausanne/Project_droso#II) Experiments on mosquitoes|collaboration with a Laboratory at the Pasteur Institute]] in Paris that works on mosquitoes to help us test whether our constructs indeed inhibit ''P. falciparum'' from infecting mosquitoes.

Latest revision as of 23:18, 27 October 2010



Overview

This page provides an overview of our project and the results we achieved.

Project idea

caption

The aim of our project is to defeat Malaria. To do so, we genetically modified a bacterium that is naturally present in Anopheles mosquitoes. Our engineered bacterium is designed to prevent malaria from infecting the mosquito. This in turn will prevent the transmission of the parasite to humans.


Our idea is to engineer Asaia, a bacterium that is naturally present in the mosquito's intestinal tract.

Asaia project overview.png

Gut.png


This bacterium would express an immunotoxin or specific proteins that either kill P. falciparum or prevent its entry into the epithelium of Anopheles.

caption caption


Our host bacterium Asaia is an organism that is not only easy to grow and to genetically manipulate but is also naturally present in the ecosystem. We aim to establish Asaia as a new chassis to give future iGEM teams the opportunity to quickly and efficiently engineer new and more potent Asaia strains. This would provide synthetic biology with a useful tool in the fight against malaria and other mosquito borne diseases.

caption


So... ASAIA is the pink power against malaria.....





For an overview of our project, you can watch our movie iGEM EPFL movie

caption

Results

caption

We established Asaia as a new chassis by providing detailed tech-sheets on how to manipulate it. We constructed several biobricks with which proteins can be produced that may block malaria infection. We also made Asaia-specific biobricks, such as the CFP construct to test expression. These tools will allow future iGEM teams to use Asaia and manipulate it to fight mosquito-borne diseases.

The expression of the proteins intended to block P. falciparum was tested in E. coli. The tests showed that the immunotoxin is expressed and it also appears in the supernatant, which is evidence for secretion. We could not show expression of the P-proteins, probably due to the AT-rich sequence.

Furthermore we tested the persistence of Asaia in D. melanogaster to see if it could be used as an alternative host to facilitate research. The results showed that Asaia is not persistent in D. melanogaster and we assume that it is because Asaia is very specific to mosquitoes.

We also established a collaboration with a Laboratory at the Pasteur Institute in Paris that works on mosquitoes to help us test whether our constructs indeed inhibit P. falciparum from infecting mosquitoes.


wrap bottom